Published in Mol Ther on May 26, 2009
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther (2010) 1.15
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev (2013) 1.05
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther (2010) 1.01
Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99
Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol (2014) 0.88
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol Ther (2013) 0.82
In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol (2015) 0.80
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Oncolytic virotherapy for ovarian cancer. Oncolytic Virother (2012) 0.77
Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. Front Oncol (2017) 0.76
Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD. J Am Soc Nephrol (2011) 0.76
Molecular imaging of oncolytic viral therapy. Mol Ther Oncolytics (2015) 0.76
Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus. Virology (2012) 0.75
Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother (2016) 0.75
The Role of Myeloid-Derived Suppressor Cells in Viral Infection. Viral Immunol (2017) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18
Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 4.06
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 2.72
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol (2003) 2.43
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest (2007) 2.36
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res (2002) 1.63
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 1.54
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer (2007) 1.40
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res (2006) 1.40
Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol (2005) 1.28
Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res (2008) 1.26
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev (2003) 1.26
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res (2007) 1.21
Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J (2003) 1.11
Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys (2007) 1.06
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res (2005) 1.05
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res (2001) 1.04
Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer (2005) 1.04
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys (2004) 0.97
Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol (2008) 0.97
Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J Immunol (2006) 0.96
Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol Immunother (2007) 0.95
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res (2004) 0.93
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res (2006) 0.92
Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med Res (2006) 0.90
Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer (2006) 0.90
In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys (2002) 0.88
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag (2007) 0.87
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol Carcinog (2009) 0.87
Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol (2005) 0.86
Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother (2001) 0.86
Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction. J Immunol (2007) 0.82
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One (2012) 1.35
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. BMC Gastroenterol (2006) 1.23
Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother (2012) 1.10
A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther (2006) 1.08
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine (2007) 1.07
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother (2008) 1.04
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila) (2010) 1.03
Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun (2008) 1.02
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02
DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02
Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virol J (2007) 1.02
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther (2010) 1.01
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer (2009) 1.01
Endoscopic retrograde cholangiography in the diagnosis and treatment of mucobilia. Scand J Gastroenterol (2008) 1.01
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01
Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther (2005) 1.01
DNA vaccines for cancer. IDrugs (2003) 1.00
A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci (2006) 1.00